Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
| العنوان: | Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma |
|---|---|
| المؤلفون: | Ludek Pour, Roman Hájek, Sebastian Gonzalez-McQuire, Lucy DeCosta, Paul Schoen, Jakub Radocha, Ivan Spicka, Michel Delforge, Marc S. Raab, Walter Bouwmeester |
| المصدر: | British Journal of Haematology |
| بيانات النشر: | John Wiley and Sons Inc., 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, overall survival, Disease, risk stratification, Malignancy, Risk Assessment, INTERNATIONAL STAGING SYSTEM, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Overall survival, Medicine, Humans, Registries, Multiple myeloma, Aged, LENALIDOMIDE, Science & Technology, algorithm, business.industry, Proportional hazards model, Haematological Malignancy, Hazard ratio, Hematology, Middle Aged, medicine.disease, Survival Analysis, DEXAMETHASONE, 3. Good health, multiple myeloma, relapsed, 030220 oncology & carcinogenesis, Relative risk, Risk stratification, Female, business, Life Sciences & Biomedicine, Algorithm, Algorithms, DARATUMUMAB, 030215 immunology, Research Paper |
| الوصف: | Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease-related factors change between diagnosis and the initiation of second-line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K-adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)-4 (highest risk) were 61·6, 29·6, 14·2 and 5·9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations. ispartof: BRITISH JOURNAL OF HAEMATOLOGY vol:187 issue:4 pages:447-458 ispartof: location:England status: published |
| وصف الملف: | Print-Electronic |
| اللغة: | English |
| تدمد: | 1365-2141 0007-1048 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19eeecf7fbc7c9288d36705ac37c2dfcTest http://europepmc.org/articles/PMC6899684Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....19eeecf7fbc7c9288d36705ac37c2dfc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652141 00071048 |
|---|